De novo AML with NPM1, FLT3/ITD and DNMT3A triple mutations
Conditions
Interventions
GVA group:VA combined with Gilteritinib regimen
Sponsors
The first affiliated hostipal of nanchang university
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Diagnosed with AML according to WHO2022 criteria; 2.AML patients with concurrent NPM1, FLT3/ITD and DNMT3A mutations; 3.De nove AML, not received other induction therapy (including chemotherapy, demethylation drugs, other targeted drugs) before enrollment (except hydroxyurea); 4.ECOG score 0-2; 5.Liver function: Total bilirubin =30ml/min; 7.Patients must be able to understand and willing to participate in the study and sign an informed consent form;
Exclusion criteria
Exclusion criteria: 1.Acute promyelocytic leukemia; 2.With central nervous system leukemia; 3.Myeloid sarcoma; 4.secondary to treated MDS, MPN or CMML; 5.Uncontrollable active infection; 6.Positive for HBV-DNA or HCV-RNA; 7.HIV infection; 8.Heart failure grade 2 or higher; 9.Pregnant or nursing patients; 10.Patients who refused to enroll in the study; 11.Patients deemed unsuitable for enrollment by the investigators;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| composite complete remission; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;remission depth;relapse-free survival; | — |
Countries
China
Contacts
Public ContactFancong Kong
The first affiliated hostipal of nanchang university
Outcome results
None listed